drugset
Drugs / Investigational drug
last change Sep 2010 re-read 3 minutes ago

Investigational drug

Developed for
colorectal neoplasm · diarrheal disease
Investigated by
Celgene Corporation · Pfizer

Trials 1

today NCT00040391 · Ph 2
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00040391 Jun 2002 → ? colorectal neoplasm, diarrheal disease Celgene Corporation Terminated No outcome recorded

Press releases naming this drug 3 releases

DateIssuerRelease
2010-09-24 Bristol-Myers Squibb 52-Week Phase 3 Study Found Investigational Drug Dapagliflozin Plus Metformin Similar to Glipizide Plus Metformin in Improving Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus bms.com ↗
2010-09-20 Bristol-Myers Squibb 24-Week Phase 3 Study Found Investigational Drug Dapagliflozin Improved Glycosylated Hemoglobin (HbA1c) When Added to Glimepiride in Adults with Type 2 Diabetes Mellitus bms.com ↗
2010-08-14 Bristol-Myers Squibb Data on Investigational Drug Belatacept in Kidney Transplant Recipients to Be Presented at 23rd International Congress of The Transplantation Society bms.com ↗

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Investigational drug ClinicalTrials.gov intervention name — accepted as the source's own label NCT00040391 ↗